توقعات سوق خدمات الحرائك الدوائية في منطقة آسيا والمحيط الهادئ حتى عام 2031 - التحليل الإقليمي - حسب نوع الدواء (الجزيء الصغير والجزيء الكبير واللقاحات)، ونوع الخدمة (ADME ما قبل السريرية والدراسات البشرية، وتحليل وإعداد التقارير PK / PD، ومحاكاة الجرعات، وتحليل المخاطر، وغيرها)، والتطبيق العلاجي (علم الأورام، والأمراض المعدية، والاضطرابات العصبية، وأمراض المناعة الذاتية، واضطرابات أمراض النساء، وأمراض القلب والأوعية الدموية، واضطرابات الجهاز التنفسي، وغيرها)، والمستخدم النهائي (شركات الأدوية والتكنولوجيا الحيوية، ومنظمة أبحاث العقود، وغيرها)
زيادة اعتماد النماذج داخل الجسم الحي وفي المختبر لفهم التباين في الحركية الدوائية يعزز سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ
إن جمع ومعالجة بيانات الحركية الدوائية الضخمة الناتجة أثناء تصنيع الأدوية هي مهام مكلفة ومملة وتستغرق وقتًا طويلاً. تسلط الطبيعة كثيفة العمالة والتكلفة لهذه المهام الضوء على الحاجة إلى نماذج مثل نماذج محاكاة الحركية الدوائية ونماذج الارتباط الحركية الدوائية داخل الجسم الحي (IVIVC) للتنبؤ بمعلمات الحركية الدوائية. نموذج محاكاة الحركية الدوائية هو أداة تفسر حركية الدواء في البيئة المعيشية في ظل ظروف محددة باستخدام نماذج حسابية ورياضية. بالإضافة إلى ذلك، يعد نموذج IVIVC جزءًا أساسيًا من عملية اكتشاف الدواء. يعد تحليل تنبؤات PK/PD في المراحل المبكرة من تطوير الدواء ضروريًا لاستراتيجيات تحسين العملاء المحتملين وأيضًا لتقليل معدلات الاستنزاف بشكل أكبر. كانت هناك تطورات كبيرة في تطوير استراتيجيات جديدة في المختبر وفي الجسم الحي لتحسين وتوصيف خصائص الحركية الدوائية. يتم اقتراح نماذج IVIVC كبديل فعال من حيث التكلفة لتقييم الخصائص الصيدلانية الحيوية التي تحلل التوافر البيولوجي للأدوية وتطبيقاتها. وبالتالي، من المتوقع أن توفر مثل هذه النماذج في الجسم الحي وفي المختبر فرصًا مربحة لسوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ في المستقبل القريب.
نظرة عامة على سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ
يُعزى نمو سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ في الصين في المقام الأول إلى سوق الأدوية الراسخة، وزيادة نفقات البحث والتطوير من قبل شركات الأدوية والأدوية الحيوية، وارتفاع عدد التجارب السريرية بسبب انخفاض تكاليف التشغيل، والسياسات التنظيمية المواتية المعمول بها. وفقًا لتقرير EFPIA المنشور في عام 2023، نما إنفاق شركات الأدوية في الصين على البحث والتطوير من 10814.23 مليون دولار أمريكي في عام 2020 إلى 12989.23 مليون دولار أمريكي في عام 2021. تمتلك الصين ثاني أكبر سوق للأدوية في العالم. يؤدي العدد المفرط للسكان في البلاد، إلى جانب ارتفاع حالات الأمراض غير المعدية والمعدية المختلفة، إلى زيادة الحاجة إلى جزيئات دوائية جديدة، مما يجعل الصين سوقًا رئيسيًا في منطقة آسيا والمحيط الهادئ.
إيرادات سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ وتوقعاتها حتى عام 2031 (مليون دولار أمريكي)
تجزئة سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ
يتم تصنيف سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ إلى نوع الدواء ونوع الخدمة والتطبيق العلاجي والمستخدم النهائي والبلد.
بناءً على نوع الدواء، يتم تقسيم سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ إلى جزيئات صغيرة وجزيئات كبيرة ولقاحات. احتلت شريحة الجزيئات الصغيرة أكبر حصة سوقية في عام 2023.
من حيث نوع الخدمة، يتم تصنيف سوق خدمات حركية الدواء في منطقة آسيا والمحيط الهادئ إلى دراسات ADME والبشرية قبل السريرية، وتحليل وإعداد التقارير عن PK / PD، ومحاكاة الجرعات، وتحليل المخاطر، وغيرها. احتل قطاع ADME ما قبل السريرية والدراسات البشرية أكبر حصة سوقية في عام 2023.
من خلال التطبيق العلاجي، يتم تقسيم سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ إلى الأورام والأمراض المعدية والاضطرابات العصبية وأمراض المناعة الذاتية والاضطرابات النسائية وأمراض القلب والأوعية الدموية واضطرابات الجهاز التنفسي وغيرها. احتل قطاع الأورام أكبر حصة سوقية في عام 2023.
من خلال المستخدم النهائي، يتم تقسيم سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ إلى شركات الأدوية والتكنولوجيا الحيوية ومنظمة أبحاث العقود وغيرها. احتل قطاع منظمة أبحاث العقود أكبر حصة سوقية في عام 2023.
حسب البلد، يتم تقسيم سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ إلى الصين واليابان والهند وأستراليا وكوريا الجنوبية وبقية منطقة آسيا والمحيط الهادئ. سيطرت اليابان على حصة سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ في عام 2023.
Allucent؛ Certara Inc.؛ Charles River Laboratories International Inc؛ Eurofins Scientific SE؛ تعد كل من PACIFIC BIOLABS وParexel International Corp وSGS SA وShanghai Medicilon Inc. وThermo Fisher Scientific Inc. من بين الشركات الرائدة العاملة في سوق خدمات الحركية الدوائية في منطقة آسيا والمحيط الهادئ.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Asia Pacific Analysis
5.1 Asia Pacific Pharmacokinetics Services Market Overview
5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Pharmacokinetics Services Market - Country Analysis
10.1 Asia Pacific
10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Shanghai Medicilon Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation
Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 27. Glossary of Terms
?
List of Figures
Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Shanghai Medicilon Inc.
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.